Eden Miller, DO
Family Medicine · Bend, ORNPI 1114997988
Payments from drug & device makers
Across 2,993 payments — averaging $568.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$635K
- Abbott$298K
- Novo Nordisk$291K
- Insulet Corporation$148K
- Boehringer Ingelheim$73K
- Bayer$71K
- plus $186K from 45 others
What the payments were for
- Consulting fees$234,50114%
- Speaking & faculty fees$1,224,85474%
- Travel & lodging$153,4259%
- Food & beverage$42,1673%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$253,537
- TRULICITY$223,107
- MOUNJARO$152,083
- Omnipod$141,013
- Ozempic$117,408
- RYBELSUS$97,857
- FREESTYLE LIBRE 3$89,129
- FreeStyle Libre$67,712
- Kerendia$64,638
- Korlym$38,989
- FreeStyle Libre Pro$37,367
- Tresiba$20,776
- TZIELD$20,738
- INVOKANA$18,545
- BAQSIMI$16,022
- FreeStyle Libre 2$13,951
- Xultophy 100/3.6$6,305
- TOUJEO$4,147
- Victoza$4,033
- AFREZZA$3,556
How this compares
$1,700,515 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 233 | $269,507 |
| JardianceEmpagliflozin | 180 | $219,295 |
| OzempicSemaglutide | 138 | $175,848 |
| TrulicityDulaglutide | 60 | $85,728 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $65,634 |
| EliquisApixaban | 24 | $28,301 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $26,987 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $25,004 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $24,297 |
| JanuviaSitagliptin Phosphate | 23 | $19,817 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $19,294 |
| NovologInsulin Aspart | 62 | $17,090 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $13,265 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $12,412 |
| KerendiaFinerenone | 13 | $11,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $634,952 | $371,161329 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $72,549 | $229,098197 claims |
| Novo NordiskOzempic, Novolog | $290,900 | $192,938200 claims |
| PfizerEliquis | $327 | $28,30124 claims |
| MerckJanuvia | $5,260 | $19,81723 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $26,583 | $19,29418 claims |
| BayerKerendia | $70,544 | $11,71513 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $108 | $10,54920 claims |
| AbbVieSynthroid | $258 | $52515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Bend
- Dana RhodeBend$14K
- Kelly ShafferBend$5K
- John DelgadoAshland$4.3M
- John MickelsonLincoln City$2.1M
- Subramaniam SeetharamanMilwaukie$1.8M
- Maureen MaysPortland$491K
- Thomas TurkRoseburg$434K
- Anil RajaniHood River$325K
- Patricia BuchananEugene$239K
- Keith KlattAstoria$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.